Research Program: Diabetes & Metabolism
- Pathogenesis of DM2 and diabetes-related syndromes
- New DM2 therapies
- Complications of diabetes
- Organ failure induced cardiovascular disease
Unique research expertise:
- (Prospective) biobank studies and computational modeling
- Fecal microbiota transplantation studies
- Clinical and experimental models (e.g. mice) for microvascular dysfunction
- Renal failure and microvascular disease development
Diabetes is a major threat to health care in the Netherlands, with 1 million patients and an expected ~30 percent increase in prevalence in the next 15 years. As obesity figures are expected to double in this period, type 2 diabetes mellitus (DM2), the Metabolic Syndrome (MetSyn) and their co-morbidities will profoundly affect our health and economy. Although it is clear that excess energy intake is the driving force for obesity, little is known about the processes that trigger the transition from the metabolically healthy to the metabolically unhealthy obese phenotype. In addition to the MetSyn, and closely linked to it, is the expanding prevalence of chronic kidney disease, which, like MetSyn has proven to be a key metabolic derangement involved in cardiovascular disease. Both conditions share epidemiological features (like premature ageing, and increasing prevalence), pathophysiological mechanisms (like disturbed microcirculatory regulation) and clinically important cardiovascular complications.
Infographics on research performed within the Diabetes & Metabolism research program.
Pathogenesis of DM2 and diabetes-related syndromes
Chronic low-grade inflammation (resulting from e.g. altered intestinal microbiome composition and nutrient overload) leads to microvascular dysfunction and peripheral insulin resistance in obese subjects. This is followed by complex inter-organ communication involving the brain, endothelium, beta cell (inflammation), bone and bone marrow/immune cells, adipose tissue and symbionts (intestinal microbiome). To disentangle this complex process, we will analyse datasets from different biobank studies (HELIUS, Hoorn and Slotervaart-OLVG Bariatric surgery cohort), and use combinations of computational models, developed in collaboration with the systems biology groups in UvA and VU/VUmc, and tissue-specific animal models.
New DM2 therapies
It is of utmost importance to dissect the underlying mechanisms that induce the comorbidities of the MetSyn and directly test and implement the diagnostic and therapeutic value of these discoveries in clinical diabetes care.
Complications of diabetes
Clearly this requires a thorough understanding of the mechanisms inducing the metabolic imbalance in subjects characterized by malign obesity with insulin resistance as well as Type 2 diabetes. In this regard the pathophysiological mechanisms behind obesity- and diabetes-associated microvascular dysfunction, which predispose to e.g. nephropathy and heart failure, are incompletely understood. The role of obesity and diabetes in diastolic heart failure is investigated in close collaboration with the Research Program Heart Failure & Arrhythmias. Early identification of persons at risk and understanding of preclinical pathology will be central to initiate proper treatment strategies and delay or reverse disease progression.
Organ failure-induced cardiovascular disease
Metabolic derangements due to organ failure represent a high risk for cardiovascular disease. However, systemic consequences of metabolic derangements are poorly understood. Impaired kidney function is a strong risk factor for mortality in heart failure patients. Our current studies focus on the mediating effects of both early and advanced renal failure on cardiovascular function. The connection between kidney dysfunction and development of vascular and cardiac dysfunction is studied within (inter)nationally-funded research consortia.
Ongoing research lines within Diabetes & Metabolism
PI’s and staff members of the Diabetes & Metabolism Research program were invited to give a short pitch about their research, funding and future plans for the coming years. This resulted in this overview and the two figures presented below.
|Prof. Marc Vervloet*||VUmc||Nephrology||Dia|
|Prof. Max Nieuwdorp* / Dr. Evgeni Levin||AMC||Experimental Vascular Medicine||Dia|
|Dr. Ed Eringa* / Dr. Erik Serne||VUmc||Physiology||Dia|
|Prof. Noam Zelcer||AMC||Medical Biochemistry||Dia|
|Dr. Onno Holleboom||AMC||Vascular Medicine||Dia|
|Dr. Joline Beulens||VUmc||Epidemiology & Biostatistics||Dia|
|Dr. Petra Elders||VUmc||General Practice and Elderly Care||Dia|
|Dr. Richard IJzerman||VUmc||Internal Medicine||Dia|
|Dr. Femke Rutters||VUmc||Epidemiology & Biostatistics||Dia|
|Prof. Frans van Ittersum||VUmc||Nephrology||Dia|
|Prof. Reinier Schlingemann / Dr. Ingeborg Klaassen||AMC||Ophthalmology||Dia|
|Dr. Coert Zuurbier||AMC||Anesthesiologie||Dia|
|Dr. Muriel Grooteman||VUmc||Nephrology||Dia|
|Dr. Irene van Valkengoed||AMC||Public Health||Dia|
|Dr. Mirjam Langeveld||AMC||Endocrinology & Metabolism||Dia|
Figure 1. Overview of Principal Investigators within the Diabetes & Metabolism Research Program. Click on 'Dia' for more information about this research line.
Figure 2. Overview of collaboration within the Diabetes & Metabolism (D&M) Research Program and between Principal Investigators of D&M and other ACS Research Programs. Lines represent ongoing collaboration between D&M Principal Investigators. Asterisks indicate program leaders: Marc Vervloet, Max Nieuwdorp and Ed Eringa.